Beacon Pointe Advisors LLC Acquires New Position in BioNTech SE (NASDAQ:BNTX)

Beacon Pointe Advisors LLC acquired a new stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The fund acquired 52,706 shares of the company's stock, valued at approximately $5,563,000.

Other hedge funds also recently made changes to their positions in the company. Truist Financial Corp bought a new stake in BioNTech during the fourth quarter valued at about $1,445,000. Fifth Third Bancorp raised its stake in BioNTech by 3,881.3% during the 4th quarter. Fifth Third Bancorp now owns 16,642 shares of the company's stock valued at $1,756,000 after purchasing an additional 16,224 shares during the period. Bamco Inc. NY raised its stake in BioNTech by 123.1% during the 3rd quarter. Bamco Inc. NY now owns 158,911 shares of the company's stock valued at $17,264,000 after purchasing an additional 87,686 shares during the period. abrdn plc purchased a new position in BioNTech in the 4th quarter worth approximately $10,961,000. Finally, Kestra Private Wealth Services LLC bought a new position in BioNTech in the 4th quarter worth approximately $938,000. 15.52% of the stock is currently owned by institutional investors.

BioNTech Trading Down 2.5 %

Shares of NASDAQ BNTX traded down $2.37 during trading hours on Friday, hitting $90.61. 471,672 shares of the company traded hands, compared to its average volume of 635,780. The company's 50 day moving average price is $90.69 and its 200 day moving average price is $95.83. BioNTech SE has a 12 month low of $85.21 and a 12 month high of $125.83. The stock has a market capitalization of $21.54 billion, a price-to-earnings ratio of 181.22 and a beta of 0.25. The company has a current ratio of 11.38, a quick ratio of 11.16 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 EPS for the quarter, missing the consensus estimate of $2.64 by ($0.59). The firm had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $2.04 billion. BioNTech had a return on equity of 0.55% and a net margin of 4.01%. On average, equities research analysts anticipate that BioNTech SE will post -1.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on BNTX shares. Canaccord Genuity Group reiterated a "buy" rating and set a $171.00 price objective on shares of BioNTech in a research report on Thursday, March 21st. JPMorgan Chase & Co. decreased their price target on shares of BioNTech from $99.00 to $90.00 and set an "underweight" rating on the stock in a research note on Friday, March 22nd. UBS Group dropped their price objective on shares of BioNTech from $110.00 to $101.00 and set a "neutral" rating for the company in a report on Wednesday, March 27th. BMO Capital Markets reduced their target price on BioNTech from $123.00 to $122.00 and set an "outperform" rating on the stock in a report on Tuesday, May 7th. Finally, TD Cowen boosted their target price on BioNTech from $95.00 to $98.00 and gave the stock a "hold" rating in a research report on Tuesday, May 7th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $117.25.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.